TuisGMAB • CPH
add
Genmab
Vorige sluiting
kr 1 587,50
Dagwisseling
kr 1 567,50 - kr 1 603,00
Jaarwisseling
kr 1 315,00 - kr 2 171,00
Markkapitalisasie
93,32 mjd DKK
Gemiddelde volume
129,59 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
CPH
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (DKK) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 6,44 mjd | 35,34% |
Bedryfskoste | 3,84 mjd | 33,14% |
Netto inkomste | 3,84 mjd | 446,94% |
Netto winsgrens | 59,70 | 304,20% |
Wins per aandeel | 0,84 | -91,36% |
EBITDA | 2,36 mjd | 31,71% |
Effektiewe belastingkoers | -6,75% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (DKK) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 21,10 mjd | -25,00% |
Totale bates | 45,81 mjd | 29,82% |
Totale aanspreeklikheid | 9,11 mjd | 147,73% |
Totale ekwiteit | 36,70 mjd | — |
Uitstaande aandele | 63,54 m | — |
Prys om te bespreek | 2,75 | — |
Opbrengs op bates | 13,26% | — |
Opbrengs op kapitaal | 16,05% | — |
Kontantvloei
Netto kontantverandering
| (DKK) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 3,84 mjd | 446,94% |
Kontant van bedrywe | 2,71 mjd | 62,20% |
Kontant van beleggings | 82,00 m | 118,55% |
Kontant van finansiering | 3,00 m | 113,64% |
Netto kontantverandering | 3,52 mjd | 491,92% |
Beskikbare kontantvloei | 1,83 mjd | 41,20% |
Meer oor
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
Gestig
1999
Webwerf
Werknemers
2 682
